Key facts
- This page summarizes David Dornan's Form 4 filing for Elevation Oncology, Inc. (ELEV).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Feb 2025, 16:15.
David Dornan - 15 Feb 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- ELEV
- Reported as of
- 15 Feb 2025
- Net transaction value
- -$2,789
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 16:15:07 UTC
- Prior SEC filing
- 20 Feb 2024
- Next SEC filing
- 18 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Yang, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Dornan filed Form 4 for Elevation Oncology, Inc. (ELEV) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 20 Feb 2024.
- Current net transaction value: -$2,789.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELEV
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,375
- Change %
- Price
- Shares after
- 9,375
- Date
- 15 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
ELEV
transaction
Common Stock
Tax liability
- Transaction value
- $2,789
- Shares
- -4,152
- Change %
- -44%
- Price
- $0.6717
- Shares after
- 5,223
- Date
- 15 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELEV
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -9,375
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 28,125
- Date
- 15 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,375
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David Dornan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F3
The RSUs do not expire; they either vest or are canceled prior to the vesting date.